Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Design of Rapid Malaria Tests Requires Improvement

By LabMedica International staff writers
Posted on 11 Jul 2011
Rapid diagnostic tests (RDT) for malaria, though simple and easy to use, are not correctly utilized or understood in less than perfect settings. More...


The RDT is used to diagnose malaria infections in tropical circumstances often by applying a drop of blood to a strip and waiting for some colored lines to appear, similar to the home pregnancy tests

Until recently treatment was initiated based on clinical suspicion, but a few years ago, the World Health Organization, (WHO, Geneva, Switzerland) advised to start treatment only after laboratory confirmation of the diagnosis. RDTs were thought to be the simple solution for diagnosing malaria infections, replacing the microscopic blood examination, which needed demanding tools, time, and expertise.

Scientists at the Institute of Tropical Medicine, (Antwerp, Belgium), tested the appropriateness of the RDTs in tropical settings. They found that existing tests for instance were not robust enough to differentiate between Plasmodium falciparum and P. vivax, a parasite from the subtropics, even if their label and even brand name suggested differently. Not all the tests reacted positively to high concentrations of parasites, as this overloading leads to a negative result or a very weak line, often read by inexperienced users as negative for malaria.

In the field, people sometimes replaced the liquid buffer in the test by tap water, or by the buffer of a different kit, because the flask was empty, or lost, or swapped, which led to false positives. The rapid tests also were not suitable to determine if treatment was successful. Some tests read positive up to weeks after the infection, even when in the mean time the infection was under control. The investigators found that some field workers suffered from presbyopia or farsightedness and needed reading glasses to conduct the test. The correct prescription spectacles were unavailable in many developing countries.

Philippe Gillet, PhD, who worked on the project, criticized the design and packaging of the RDTs. The instructions were in small print and in a complicated jargon, with unclear reading scales, and the pipettes were problematic to use. He said, " Not everything should be blamed on the manufacturers as all of it easily and cheaply to remediate. It already would make a large difference if the WHO and European Union would sharpen their rules for registration." When Dr. Gillet was in Belgium, Congo, Cuba, and Cambodia, he asked health workers about the international danger symbols on the products, less than half of them could give the right answers.

Related Links:

World Health Organization
Institute of Tropical Medicine



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hematology Analyzer
Medonic M32B
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.